
Browsing restrictions can be lifted for a fee.
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products. It offers sterile ophthalmic preparations comprising gels, suspensions, solutions, and emulsions; hormone preparations, which primarily cover birth control and oral suspension for cancer related cachexia; external use preparations comprising ointments; and other oral preparations, which are in oral dosage forms, such as powders, troches, tables, film coated tablets, chewables, and capsules for the treatment of colds, gastrointestinal issues, or other indications. The company was founded in 1974 and is based in Tainan City, Taiwan. Winston Medical Supply Co., Ltd. is a subsidiary of Medigen Biotechnology Corp.
6817
溫士頓
0.24%
(0.00)
The most recent financial report for 溫士頓 (6817) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6817's short-term business performance and financial health. For the latest updates on 6817's earnings releases, visit this page regularly.
According to historical valuation range analysis, 溫士頓 (6817)'s current price-to-earnings (P/E) ratio is 12.6, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 溫士頓 (6817) reported an Operating Profit of 81.43M with an Operating Margin of 22.69% this period, representing a growth of 4.52% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 溫士頓 (6817) announced revenue of 358.83M, with a Year-Over-Year growth rate of 8.88%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 溫士頓 (6817) held Total Cash and Cash Equivalents of 356.4M, accounting for 0.42 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 溫士頓 (6817) achieved the “three margins increasing” benchmark, with a gross margin of 44.53%%, operating margin of 22.69%%, and net margin of 18.53%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6817's profit trajectory and future growth potential.
According to the past four quarterly reports, 溫士頓 (6817)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 3.61. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
溫士頓 (6817)'s Free Cash Flow (FCF) for the period is 136.84M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 7.83% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.